Editas wins Australian clearance to start Phase 1/2 EDIT-401 trial in HeFH patients

Bitget2026/10/08 11:02

Editas Medicine received Australian ethics clearance to start dosing in a Phase 1/2 trial of EDIT-401 for HeFH. The program completed the TGA Clinical Trial Notification process; a New Zealand regulatory review is ongoing. First safety and tolerability data are expected in Q1 2027; Part 1 topline safety and efficacy are targeted for later 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080700PRIMZONEFULLFEED9841763) on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41